- Home
- IMCR vs DHT Comparison
IMCR vs DHT Comparison
Compare IMCR & DHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | DHT |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United Kingdom | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.9B |
| IPO Year | 2016 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IMCR | DHT |
|---|---|---|
| Price | $28.57 | $18.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $66.33 | $19.33 |
| AVG Volume (30 Days) | 426.3K | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.36% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $8.85 |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | $115.84 | ★ $12.73 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $10.61 |
| 52 Week High | $40.71 | $20.55 |
Technical Indicators
Market Signals| Indicator | IMCR | DHT |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 61.73 |
| Support Level | $28.09 | $16.98 |
| Resistance Level | $31.56 | $18.80 |
| Average True Range (ATR) | 1.24 | 0.60 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 41.08 | 91.49 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.